Skip to main content
. 2023 Nov 23;15(12):6427–6435. doi: 10.21037/jtd-22-1604

Figure 2.

Figure 2

Kaplan-Meier curve showing PFS in patients receiving durvalumab for NSCLC that developed pneumonitis vs. those that did not up to 48 months. PFS, progression-free survival; NSCLC, non-small cell lung cancer.